Dr
HAJAR
MOUDHICH
Dr
HAJAR
MOUDHICH
Head of Quality, Health, Safety and Environment Department/ Deputy Responsible Veterinarian/ Head of International Relations and Cooperation
BIOPHARMA
LinkedIn
View profileBiography
Hajar Moudhich, born on August 11, 1987, is a distinguished Moroccan veterinarian with a doctorate from the Hassan II Agronomic and Veterinary Institute in Rabat, where she focused her research on bovine hemoparasitosis. Her professional journey began with the production of bacterial vaccines at BIOPHARMA, where she ensured compliance with Good Manufacturing Practices (GMP) and led several research projects.
Since 2015, Hajar has been pivotal as the Head of Quality Assurance at BIOPHARMA, successfully managing projects that led to GMP certification, ISO 17025, and ISO 9001 accreditations. In April 2023, she advanced to Head of the Quality, Hygiene, Safety, and Environment Service. Her expertise extends to internal audits and serving as a Veterinary Delegate.
Hajar is an active member of several professional organizations; Her technical skills are complemented by extensive training in GMP, ISO standards, and biosafety, making her a versatile leader in veterinary medicine and quality management. Hajar’s contributions are further highlighted by her role in the scientific committee at BIOPHARMA, where she continues to influence veterinary practices and safety standards.
Research interests
Industrial production of veterinary vaccines, fermentation and cell culture processes, process validation, technology transfer, regulatory compliance, quality systems, and continuous improvement in pharmaceutical manufacturing environments. Projects you're working on
I am currently involved in a project aimed at developing and producing a veterinary vaccine against equine respiratory diseases, using field-isolated strains to ensure better epidemiological relevance and efficacy. Discipline
Bacteriology Bio-manufacturing Bioinformatics Cellular biology Challenge model development Challenge study design Clinical trials – efficacy Clinical trials – safety Commercialisation Deployment Economics Epidemiology Ethics Formulation technology Immunology – B-cells Immunology – T-cells Molecular biology Pharmacovigilance QC test development Quality assurance Registration Regulation Safety evaluation Virology Host species
Camels Cats Cattle Dogs Horses Poultry Small ruminants Zoonoses Pathogen
Bacteria Bacteria›Brucella Bacteria›Clostridia Bacteria›E. coli Bacteria›Mycobacteria bovis Bacteria›Mycoplasma Viruses Viruses›Adenovirus Viruses›African horse sickness virus Viruses›Bluetongue virus Viruses›Bovine viral diarrhoea Viruses›Capripoxvirus Viruses›Coronavirus Viruses›Foot-and-mouth disease virus Viruses›Infectious bursal disease virus Viruses›Infectious pancreatic necrosis virus Viruses›Influenza virus Viruses›Mareks disease virus Viruses›Newcastle disease virus Viruses›Paramyxoviruses Viruses›Parvovirus Viruses›Peste des petits ruminants virus Viruses›Poxviruses Viruses›Rabies virus Viruses›Respiratory syncytial virus Viruses›Rift Valley fever virus Viruses›Rotavirus Stage of vaccine development
Antigen discovery and immunogen design Clinical trials Commercialisation Correlates of protection – immunomonitoring Deployment Field trials Marketing Pre-clinical trials Vaccine delivery